Novo Nordisk, FDA and Ozempic

Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
US FDA says shortage of Novo's weight-loss drug resolved
The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and diabetes drugs. All doses of Novo's diabetes treatment Ozempic and weight-loss drug Wegovy were listed as available on the FDA's website in October,
Novo Nordisk up 6%, Hims & Hers down 15% as FDA says Ozempic shortage over
Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of
Novo’s Ozempic, Wegovy Shortage Ends, Threatening Copycats
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular medications.
Hims & Hers Health Shares Tumble After Novo Nordisk Says Wegovy, Ozempic Shortage is Over
Hims & Hers Health shares tumbled after a leading competitor said a shortage of its weight-loss treatments has been resolved, raising questions about the company's prospects in the space. Shares tumbled 21% to $52.
FDA to spare compounders as Novo Nordisk’s Ozempic supply begins to improve
The U.S. FDA announced Friday that it would refrain from penalizing makers of compounded versions of Novo Nordisk’s (NVO) weight loss/obesity drugs as supply conditions for the GLP-1s improve after an official end to their shortage.
Novo Nordisk shortage of Ozempic and Wegovy ends, threatening compounders
The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for compounding pharmacies to make copies of Ozempic and Wegovy.
Novo Nordisk A/S (NVO): Is It The Most Oversold Healthcare Stock to Buy Now?
We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEO
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this year.
Does Medicare Cover Ozempic?
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Why Novo Nordisk Stock Popped on Friday
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
Yahoo Finance1mon
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
The two drugs are Novo Nordisk's top growth drivers, and together comprise over 60% of its total revenue. However, the Centers for Medicare and Medicaid Services (CMS) could soon throw a monkey ...
STAT20h
Dozens of attorneys general urge FDA to crack down on counterfeit obesity drugs
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...